10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2014 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2014 10-K (Filed: Feb 13, 2015) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2014 | Dec 31, 2013 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 5,571 | 3,586 |
| Marketable securities, current | 1,864 | 939 |
| Receivables | 3,390 | 3,360 |
| Inventories | 1,560 | 1,498 |
| Deferred income taxes, current | 1,644 | 1,701 |
| Prepaid expenses and other | 470 | 412 |
| Assets held-for-sale | 109 | 7,420 |
| Total Current Assets | 14,608 | 18,916 |
| Property, plant and equipment | 4,417 | 4,579 |
| Goodwill | 7,027 | 7,096 |
| Other intangible assets | 1,753 | 2,318 |
| Deferred income taxes | 915 | 508 |
| Marketable securities, noncurrent | 4,408 | 3,747 |
| Other assets | 621 | 1,428 |
| Total Assets | 33,749 | 38,592 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term borrowings | 590 | 359 |
| Accounts payable | 2,487 | 2,559 |
| Accrued expenses | 2,459 | 2,152 |
| Deferred income, current | 1,167 | 756 |
| Accrued rebates and returns | 851 | 889 |
| Income taxes payable, current | 262 | 160 |
| Dividends payable | 645 | 634 |
| Liabilities related to assets held-for-sale | 4,931 | |
| Total Current Liabilities | 8,461 | 12,440 |
| Pension, postretirement, and postemployment liabilities | 1,115 | 718 |
| Deferred income, noncurrent | 770 | 769 |
| Income taxes payable, noncurrent | 560 | 823 |
| Other liabilities | 618 | 625 |
| Long-term debt | 7,242 | 7,981 |
| Total Liabilities | 18,766 | 23,356 |
| Commitments and contingencies (Note 22) | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,212 in 2014 and 4,369 in 2013, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2014 and 2013 | 221 | 221 |
| Capital in excess of par value of stock | 1,507 | 1,922 |
| Accumulated other comprehensive loss | (2,425) | (2,141) |
| Retained earnings | 32,541 | 32,952 |
| Less cost of treasury stock - 547 million common shares in 2014 and 559 million in 2013 | (16,992) | (17,800) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 14,852 | 15,154 |
| Noncontrolling interest | 131 | 82 |
| Total Equity | 14,983 | 15,236 |
| Total Liabilities and Equity | 33,749 | 38,592 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2014 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |